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Between April 2014 and March 2015, the South 
African National Health Laboratory Service (NHLS) 
CD4 network provided 3.9 million CD4 test results 
to referring health centres and clinics across South 
Africa (SA). Although there is an extensive network 
of ~260 national laboratories that provide general pathology services 
and 59 specialised labs that provide CD4 testing, gaps in service have 
been identified in remote districts (i.e. 14/53 districts).[1] An integrated 
tiered service delivery model (ITSDM)[1] consisting of six service 
tiers has been described in line with World Health Organization 
(WHO) recommendations,[2] which incorporates existing services 
and provides for extension of services into remote, under-serviced 
areas to address gaps in service delivery. 
ITSDM tiers 4 and 5, at the higher end, are the backbone of existing 
CD4 services that currently provide high-volume testing in metro-
politan areas across SA; a harmonising sixth tier (tier 6) provides for 
external quality assessment, as well as network and training support. 
Three new tiers of service are proposed in the ITSDM, to supplement 
tiers 4 and 5 and enable extended service delivery across the country into 
areas with service deficiencies. Firstly, tier 3/community laboratories 
can be established in an existing small general pathology laboratory, 
processing up to 150 samples per day using traditional or operator-
independent flow cytometry-based technologies (Beckman Coulter 
XL,[3] Beckman Coulter Aquios[4] and Becton Dickinson FACSCount 
(BDS, USA)[5]). Secondly, services are further extended with two point-
of-care (POC) tiers into areas without reasonable access to a laboratory. 
The first POC tier/tier 2 is essentially a POC ‘hub’ or mini-laboratory 
that can provide services for up to ten referring community health/
primary health clinics (CHCs/PHCs) offering antiretroviral therapy 
within a radius of 50 km and be managed by a single technician 
(or recently a Health Professions Council of South Africa-approved 
cadre ‘phlebotomy technician’)[6] who will operate multiple POC 
technologies to provide a range of basic HIV and/or TB services. 
These facilities can also be implemented into existing small NHLS 
laboratories and will process <50 but >10 samples per day, using CD4 
technologies designed to be used at the POC, including FACSPresto 
(BDS, USA)[7] and Pima (Alere, SA). A mini-laboratory can also be set 
up in a designated area within an existing CHC. All are managed and 
overseen by the NHLS. The last ITSDM tier 1 provides similar services 
to tier 2 but will operate in remote, hard-to-reach sites as stand-alone 
facilities, providing services for the local clinic only. Attending nursing 
personnel or a phlebotomy technician could take responsibility for 
the CD4 testing. These extended tiers, which supplement the high-
volume testing sites to provide full national service coverage, offer an 
optimised public health approach to balance overall programmatic 
costs,[8] while lowering and ensuring reliable turnaround time (TAT), 
irrespective of where the test request originates and in line with local 
HIV treatment algorithm requirements.[9] 
Pixley ka Seme, a remote district of SA and one of nine pilot 
sites for the introduction of National Health Insurance in SA, was 
identified through ITSDM planning as a district with poor access 
to CD4 testing. The existing De Aar laboratory in the district 
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 Background. The CD4 integrated service delivery model (ITSDM) provides for reasonable access to pathology services across South Africa 
(SA) by offering three new service tiers that extend services into remote, under-serviced areas. ITSDM identified Pixley ka Seme as such 
an under-serviced district. 
Objective. To address the poor service delivery in this area, a new ITSDM community (tier 3) laboratory was established in De Aar, SA. 
Laboratory performance and turnaround time (TAT) were monitored post implementation to assess the impact on local service delivery.
Methods. Using the National Health Laboratory Service Corporate Data Warehouse, CD4 data were extracted for the period April 2012 - 
July 2013 (n=11 964). Total mean TAT (in hours) was calculated and pre-analytical and analytical components assessed. Ongoing testing 
volumes, as well as external quality assessment performance across ten trials, were used to indicate post-implementation success. Data were 
analysed using Stata 12.
Results. Prior to the implementation of CD4 testing at De Aar, the total mean TAT was 20.5 hours. This fell to 8.2 hours post 
implementation, predominantly as a result of a lower pre-analytical mean TAT reducing from a mean of 18.9 to 1.8 hours. The analytical 
testing TAT remained unchanged after implementation and monthly test volumes increased by up to 20%. External quality assessment 
indicated adequate performance. Although subjective, questionnaires sent to facilities reported improved service delivery.
Conclusion. Establishing CD4 testing in a remote community laboratory substantially reduces overall TAT. Additional community CD4 
laboratories should be established in under-serviced areas, especially where laboratory infrastructure is already in place. 
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provides some basic pathology services across a service precinct 
of 103  410 km2 and eight municipalities. The local population of 
~186 000 people attend multiple health facilities within a radius of up 
to 260 km, including ten local hospitals (hospital wards) and 34 PHC 
clinics. More than 70% of the population is under the age of 40 years, 
and the district has an HIV prevalence of 18.4% (2012 statistics).[10] 
A tier 3/community laboratory CD4 service was piloted at the 
existing De Aar NHLS laboratory to address the historically poor 
CD4 TAT and gaps in service. The impact of the newly implemented 
tier 3/community CD4 laboratory service in De Aar was assessed by 
reviewing the TAT before and after the implementation. Success of the 
implementation was measured through review of ongoing monthly 
CD4 test volumes and external quality assessment performance of 
the De Aar laboratory.
Methods
CD4 testing was implemented and training given at the De Aar 
laboratory in December 2012 using the Beckman Coulter Epics XLTM 
flow cytometry platform and the PanLeucogating method. [3] Using 
Corporate Data Warehouse (CDW), CD4 sample level data were 
extracted for the period April 2012 - July 2013 (N=11 964) for the 
wider Pixley ka Seme health area. This included pre-implementation 
data of CD4 workload referred to regional CD4 testing laboratories 
for testing (Kimberly or Pelonomi) as well as data from the De Aar 
laboratory itself post implementation (sample volume data were 
extended to December 2014). The specimen data extract included 
the laboratory information system (LIS) episode number (which 
provided evidence of volumes of tests), province, health district and 
the health facility location name and code from which the sample 
was sent. Data that were collected with a listed LIS ‘tested date’ 
between 1 April and 30 November 2012 were categorised as ‘pre-
implementation’. Data collected after January 2013 were categorised 
as ‘post-implementation’. The reporting measures included CD4 
monthly test volumes and mean TATs. To establish TAT, the following 
LIS date and time fields were used, including: (i) ‘registered date’, 
when samples are registered (order entry) at the referring hub or 
laboratory; (ii) ‘test registered date’ describing when samples are 
registered/received at the CD4 testing laboratory; (iii) ‘tested date’, 
when the CD4 Epics XLTM CD4 result data are downloaded into 
the LIS; and lastly, (iv) ‘reviewed date’, when a medical technologist 
authorises the CD4 results for printing (by SMS (text message)) at the 
original referring site. Using the LIS date and time fields, four distinct 
TAT measures were identified for this analysis: (i) ‘PRE-LAB TAT’ 
(pre-analytical component), test registered date minus registered 
date (interlaboratory or processing hub referral time); (ii) ‘IN-LAB 
TAT’, tested date minus test registered date (analytical processing 
Fig. 1. Map of distribution of existing NHLS CD4 service (as pale yellow and pale orange circular service precincts) in relation to >4 000 referring PHC clinics 
(black dots), distributed across 53 defined districts in SA. A new community CD4 service (tier 3) was established in Pixley ka Seme (demarcated as a red 
circle), at the De Aar NHLS service laboratory in 2012, to address poor access to CD4 testing in this district identified through ITSDM planning. Insert: Map 
of the greater Pixley ka Seme district reveals existing referring health facilities serviced by the De Aar laboratory. Although the De Aar laboratory offered 
basic pathology testing, CD4 testing was referred to nearby centralised facilities including Kimberley (243 km away), Upington (433 km) and Bloemfontein/
Pelonomi (362 km) laboratories. Red circles are estimated existing precinct service coverage.
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time); (iii) ‘RVW-TAT’, reviewed date minus tested date (time to 
authorised results following analysis); and lastly (iv) ‘TOTAL-TAT’, 
reviewed date minus registered date. Anomalies, due to a computer 
internal data and time setting for the decentralised Disa*Lab LIS 
used previously, that were noted in the LIS date and time fields were 
excluded (e.g. a reviewed date in the year 1800 (1800/01/01 00:01). 
This affected only 0.3% (36/11 964) of the total data set. All data were 
analysed using Microsoft Excel and Stata 12.
External quality assessment (EQA) performance of the De Aar 
laboratory on the NHLS CD4 Proficiency Testing (PT)/African 
Regional External Quality Assessment (AFREQAS) programme[11] 
was obtained from the De Aar laboratory from trial 19 (May 2013) 
through to trial 30. Each AFREQAS trial consists of two proficiency 
material samples, i.e. one normal (CD4 count >500 cells/µL) and one 
low (CD4 count <200 cells/µL) sample. Performance of the laboratory 
is measured against the consensus pooled mean result of each 
trial, and is regarded as adequate if the CD4 result reported by the 
laboratory falls within 2 standard deviations (SDs) of the consensus 
pooled trimmed-mean CD4 result.
Results
The geographical relationship of 44 referring health facilities and 
the De Aar laboratory in the Pixley ka Seme district to the pre-
implementation referral CD4 labs in the Free State (Pelonomi) or 
Kimberly (North West) is shown in Fig. 1. This figure also gives 
information about existing CD4 service coverage in SA, showing 
paucity of local services in the Pixley ka Seme district, in contrast 
to the relatively well-serviced areas elsewhere in the country. Fig. 2 
reveals the impact on TAT of longer (shorter) distances required to 
refer samples for testing elsewhere; the monthly mean TOTAL-TAT 
for Pixley ka Seme before implementation ranged from 12 to 38 hours 
(the majority of samples were referred from the De Aar laboratory to 
the Kimberley laboratory for testing). A marked difference in mean 
TOTAL-TAT was noted, reducing from a median of 20.45 hours 
before implementation to 8.17 hours after December 2012 (Fig.  2). 
Following a 2-month settling-in period, by March 2013 (mean 
TOTAL-TAT of 16 hours was recorded), the TOTAL-TAT steadily 
decreased to a mean of 12 hours and stabilised at 5 hours or less by 
May 2013. This trend has continued beyond the TAT data extraction 
period (data not shown). 
To assess what component of TAT contributed to TOTAL-TAT, 
the various components of TAT were assessed including PRE-LAB 
(pre-analytical), IN-LAB and RVW-TAT (both analytical), before 
(pre-) and after (post-) implementation (Fig. 2). The pre-analytical 
component of the TOTAL-TAT was noted to contribute the largest 
proportion of TOTAL-TAT in the pre-implementation time period. 
During these pre-implementation months, April - November 2012, 
pre-analytical TAT showed marked daily variability (with a range of 
TAT from 4 hours in April 2012 extending to 45 hours in October 
2012). After the De Aar CD4 lab was established, the mean PRE-LAB 
decreased from an average of 18.99 hours to 1.82 hours, reducing the 
mean monthly TOTAL-TAT substantially. By June 2013, the mean 
pre-analytical TAT had stabilised at ~2 hours. Evidence of an initial 
learning curve was revealed during the first 2 months, i.e. January 
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Fig. 2. Breakdown of TOTAL-TAT in the pre-implementation (April - November 2012) and post-implementation phases (January - July 2013), into mean 
PRE-LAB TAT (blue), mean IN-LAB TAT (black) and mean RVW-TAT (grey). In the pre-implementation phase, the mean PRE-LAB TAT was 4 - 45 
hours and the mean IN-LAB TAT 2 - 11 hours. In contrast, in the post-implementation period, the mean PRE-LAB TAT decreased to <6 hours but with no 
significant change in mean IN-LAB TAT at 4 - 13 hours (expected because of use of standardised testing protocols).
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and February 2013, where an IN-LAB TAT of 11 and 13 hours was 
noted respectively (highlighted in Fig. 2). However, the IN-LAB/ 
analytical TAT subsequently decreased to that expected of a typical 
CD4 laboratory processing time as staff became more familiar 
and integrated the new CD4 testing into their existing workflow 
(attributable to the adherence to the standardised NHLS CD4 testing 
procedures that are used irrespective of where testing is performed 
across the NHLS CD4 network). Further analysis of the TOTAL-TAT 
data revealed that before implementation of the De Aar CD4 site, 54% 
of CD4 samples were reported within a TOTAL-TAT of ≤12 hours. 
After implementation however, 81% of samples had a TOTAL-TAT of 
≤12 hours (Fig. 2). In a detailed subanalysis, CD4 sample results with 
a TOTAL-TAT between 13 and 24 hours decreased from 26% to 13%; 
those with a TOTAL-TAT >24 hours, decreased by 150%, from 19% 
to 6% of all samples tested. Overall, the percentage of samples with a 
≤24 hours TOTAL-TAT increased from 81% before implementation 
to 94% post implementation. 
Details of month-to-month variation of workload volume post 
implementation can be seen in Fig. 3, extending to December 2014. 
Pre-implementation volumes were divided into ‘referred to and tested 
at Kimberley’ (mean of 571 samples/month) and ‘referred by De Aar 
and tested in Kimberley’ (mean 112 samples per month). After CD4 
testing started at De Aar in December 2012, some samples were still 
referred through De Aar to be tested in Kimberley (~125 per month). 
This was attributed to periods of downtime on the instrument (owing 
to long distances, reaction time of engineers to get instruments 
operational is prolonged) and/or availability of staff to operate the 
system. However, the majority of samples from the district are now 
tested at the De Aar laboratory (monthly mean of 358 samples). Some 
samples are still referred directly to Kimberley at a mean rate of 287 
per month and reflect NHLS business decisions to optimally refer 
testing from sites that lie far north in Pixley ka Seme to the nearest 
testing facility (in this instance Kimberley). 
External quality assessment performance
During the post-implementation period of this study, ten trials (20 
EQA samples) were tested by the De Aar laboratory. Across each 
trial, proficiency panel results (CD4 normal and CD4 low, as CD4 
count and CD4% of lymphocytes (CD4%L)) were recorded within 
the required 2 SDI range (Fig. 4, shaded area; −2 - +2, with zero 
as the ideal target). There was an initial outlier EQA result on the 
normal CD4%L (intervention revealed a transcription error due 
to inexperience of staff filling in the EQAS submission form). The 
average SDI of the De Aar CD4 laboratory across all trials was −0.21, 
confirming that performance was well within the expected range. 
However, SDI results from Trial 23 fell outside the expected range for 
both absolute count and CD4%L (intervention and corrective action 
revealed that new staff had been appointed without proper EQAS 
training). The laboratory has sustained acceptable performance on 
the scheme for the remaining reported trials (Fig. 4).
Discussion
CD4 testing has been used for establishing immune suppression and 
disease progression in HIV-positive patients, enabling identification 
of those patients who are eligible for antiretroviral therapy and/
or treatment for opportunistic infection. Current SA treatment 
guidelines[9] require that newly identified HIV-positive patients 
return to the clinic facility within 7 days of testing HIV-positive[12] to 
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Fig. 3. Total volumes of CD4 tests performed per month before (pre-) and after (post-) CD4 laboratory implementation at De Aar. Volumes of samples ‘referred 
to and tested at Kimberley’ (‘RT Kimberley’), are shown in contrast to samples ‘referred to and tested at De Aar’ (‘RT De Aar’). A small fraction of samples 
referred to De Aar for testing is still tested at Kimberley (‘R De Aar T Kimberley’/‘RT Kimberley’).
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receive the results of the required pathology 
work-up, including CD4 results outlined 
in the treatment guidelines. Since the 
commencement of the South African HIV/
AIDS Comprehensive Care, Management 
and Treatment programme, laboratory-
based CD4 testing has been the mainstay 
of the CD4 services provided.[3,13] Locally, 
the NHLS provides access to the majority 
of these CD4 results within a 24-hour TAT 
to facilitate algorithm management.[1] In the 
rural areas of the Northern Cape Province, 
the closest tier 4/regional and tier 5/metro 
centralised laboratories are too far (up to 
300 - 400 km) away to ensure reliable CD4 
TATs.[1] 
Several service delivery options were con-
sidered for Pixley ka Seme area that would 
improve TAT, while taking into account 
the vast distances between facilities in the 
district and proximity to the closest testing 
facilities. The first service option con-
sidered CD4 testing on a mobile unit,[14] 
with various scenarios proposed. These 
included a once-per-month service option 
(costing ZAR125.47/test), a fortnightly 
option (ZAR201.22/test/visit), a weekly 
option (ZAR352.73) as well as a daily service 
delivery option (ZAR1 564.75/test).[14] This 
approach was abandoned because of the 
prohibitively high, unaffordable cost per test 
required to maintain reasonable access to 
services on at least 4 days a week.
Implementation of widespread POC CD4 
testing services in all 44 referring facilities 
was also considered as the second option, 
potentially providing immediate patient 
access to results and purporting the added 
advantage[13] of improving the number of 
patients enrolled into care. Aside from the 
logistical and other problems of widespread 
POC technology implementation,[1] overall 
voluntary counselling and testing process 
compliance has been reportedly poor,[15] with 
specific areas of concern including specimen 
collection methodology and availability 
of equipment, e.g. gloves, etc., to perform 
the test (procurement challenges), poor 
or misuse of available consumables, poor 
adherence to stipulated incubation times 
before reading HIV rapid test results, lack 
of staff training and inconsistent or absent 
quality assurance practices.[15] This approach 
was also abandoned in the NHLS because of 
the substantively higher programmatic costs 
that could be incurred by implementing 
POC across multiple clinics; a CD4 test 
performed at the POC was shown to cost 
5 - 7 times more than providing a CD4 test 
in a laboratory.[8] 
#CD4: Normal
%CD4: Low#CD4: Low
%CD4: Normal
Fig. 4. Performance on EQA after tier 3 CD4 service implementation at De Aar. Radial performance plots show laboratory performance on trials 19 through 
30. A1 and A2 represent data from the normal CD4 count proficiency material while B1 and B2 depict results from low CD4 count EQA material. The 
acceptable range of −2 - +2 SDI is shaded with a solid line indicating the ideal of zero. An initial outlier on trial 19 was shown to be a transcription error. 
Another outlier was noted for trial 23 (both parameters). Intervention and corrective action ensured that future performance returned to expected. 
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The third service delivery of providing a local small community 
laboratory was provided for in the ITSDM. This study confirms 
that the establishment of an ITSDM tier 3 laboratory in a remote, 
under-serviced area of SA with historically poor TAT can lead to a 
dramatic improvement of local service delivery. There was a notable 
reduction in the pre-analytical TAT after CD4 testing was started in 
the De Aar laboratory, from 18 hours when samples were referred 
in centrally for testing to the Kimberley laboratory, down to a 
mean of 1.82 hours post implementation. Although anecdotal, the 
responses from local clinics were favourable; a moderate increase in 
the number of CD4 tests requested post implementation (see Fig. 3) 
attested to this. Despite an initial hiccup of increased analytical/
IN-LAB TAT attributable to learning curve, IN-LAB TAT fell 
to expected levels as staff became better acquainted with NHLS 
standardised operating procedures. This is an encouraging aspect, 
and together with the satisfactory EQA review of the performance of 
the site, suggests that any small laboratory, with few staff members, 
is likely to cope well with an add-on tier 3 service. Although some 
CD4 testing was still referred to the larger metropolitan tier 4 lab 
at Kimberley after implementation, because referring clinic sites 
were in closer proximity to this centre (see Fig. 3), a moderately 
increased local workload (Fig. 3) was noted post implementation at 
De Aar. This is also an important outcome. If smaller laboratories 
are capable of an additional modest workload, without major 
implementation, overhead and staffing costs, this could potentially 
save the country millions of rands while extending the footprint of 
laboratory services. [1,8] Previous cost modelling work in Pixley ka 
Seme district[8] reveals that establishing this small tier 3 site may cost 
marginally more per CD4 test than a CD4 tested in a centralised 
larger laboratory (ZAR28.62/USD2.06 at exchange rate of ZAR13.90 
per USD on 20 November 2015). This is, however, substantially 
cheaper than implementing widespread use of POC technology 
(44 tier 1 facilities) across the district’s 44 clinic sites, where it has 
been estimated that widespread CD4 provided at the POC could 
cost Pixley ka Seme in excess of ZAR4.5  million/USD325 700 (at 
ZAR449.25/USD32.32 per test) as opposed to an estimated ZAR1.03 
million/USD74 000 needed to provide a tier 3 laboratory-based 
service offering the same number of tests per formed, but at the 
De Aar facility. The additional benefit, as a trade-off for the small 
incremental cost, is that there are less local logistics costs incurred, 
as testing is performed on-site, coupled with better sample integrity 
and significantly improved local TAT – all of which has positive 
implications for better patient management. 
Conclusion
The extended decentralised tier 3/community laboratory imple-
men tation at the De Aar laboratory in Pixley ka Seme offers a 
compromise between cost and accessibility, with a small incre-
mental cost (ZAR28.63/USD2.06)[8] but substantively lower TAT, 
while maintaining a quality of testing expected from a larger lab-
oratory. Owing to the success of the De Aar pilot site, additional 
implementation sites, also identified through ITSDM planning, have 
been proposed to improve and extend services elsewhere in under-
serviced districts using existing NHLS laboratories, including Aliwal 
North (Eastern Cape), Lephalale (Limpopo), St Patricks (Eastern 
Cape) and Vredenburg (Western Cape).
Study limitations
Owing to the absence of an end-to-end sample tracking system, 
it was not possible to report TAT for afferent (time from sample 
collection by the courier at the health facility to registration on 
the LIS) and efferent (time from result authorisation to result 
delivery to the health facility) phases of the laboratory value chain. 
Additionally, for interlaboratory referrals we were unable to identify 
whether delays were due to courier delays or to pre-analytical 
receiving office delays.
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